Tonyali, O. Et Al. 2012. Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.138, no.12 , 2145-2151.

Tonyali, O., Coskun, U., Sener, N., İNANÇ, M., Akman, T., Oksuzoglu, B., ... Ozdemir, N. Y.(2012). Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.138, no.12, 2145-2151.

Tonyali, Onder Et Al. "Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer," JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.138, no.12, 2145-2151, 2012

Tonyali, Onder Et Al. "Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.138, no.12, pp.2145-2151, 2012

Tonyali, O. Et Al. (2012) . "Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.138, no.12, pp.2145-2151.

@article{article, author={Onder Tonyali Et Al. }, title={Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer}, journal={JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY}, year=2012, pages={2145-2151} }